Tiglutik(riluzole)
Tiglutik 50 MG in 10 mL Oral Suspension
NO BOXED WARNING
Dosage & Administration
Get Your Patient on Tiglutik
See your patient's specific prior authorization requirements including coverage restrictions and step therapies
Or select your Insurance from the list below:
Tiglutik Prescribing Information
Tiglutik Prior Authorization Resources
Most recent state uniform prior authorization forms
Verified: Sep 24, 2024Arizona - Uniform Prior Authorization Form
Verified: Sep 24, 2024Colorado - Uniform Prior Authorization Form
Verified: Sep 24, 2024Hawaii - Uniform Prior Authorization Form
Verified: Sep 24, 2024Illinois - Uniform Prior Authorization Form
Verified: Sep 24, 2024Indiana - Uniform Prior Authorization Form
Verified: Sep 24, 2024Louisiana - Uniform Prior Authorization Form
Verified: Sep 24, 2024Minnesota - Uniform Prior Authorization Form
Verified: Sep 24, 2024New Hampshire - Uniform Prior Authorization Form
Verified: Sep 24, 2024New Mexico - Uniform Prior Authorization Form
Verified: Sep 24, 2024Oregon - Uniform Prior Authorization Form
Verified: Sep 24, 2024Texas - Uniform Prior Authorization Form
Verified: Oct 05, 2024Washington - Uniform Prior Authorization Form
Verified: Oct 05, 2024Wisconsin - Uniform Prior Authorization Form
Benefits investigation
Tiglutik Preferred Pharmacy
Tiglutik Financial Assistance Options
Copay savings program
Learn More
Overview
- Reduce patient OOP costs for drug (and occasionally for drug administration/infusion costs or drug-related test costs)
Patient benefit
- A portion (or all) of patient OOP (deductible, copay), typically up to monthly and/or annual max
Patient eligibility
- Patient must enroll or activate (may permit HCPs to enroll on patient’s behalf for HCP-administered drugs)
- Generally, must have commercial insurance (rarely, may permit uninsured patients to use)
- May never be used with government insurance
How to sign up
- Cards may be downloadable digital cards or hard copies
- Some pharmacos offer debit cards with pre-loaded copay benefit
- Typically, available through multiple channels (e.g., rep to HCP to patient; pharmacy to patient; patient via website, Hub live agent, or copay vendor (live agent or IVR); patient and HCP via Hub enrollment form)
- Some HCP-administered product programs permit HCPs to enroll on a patient’s behalf through via Hub form
Tiglutik PubMed™ News
Tiglutik Patient Education
Getting started on Tiglutik
Instructions For Use: Amyotrophic Lateral Sclerosis (ALS)
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Open Camera on Phone
Scan QR Code & Tap Link
To share resource; ask patient to:
1.Pull out phone
2.Open camera
3.Scan QR code with camera
4.Tap link
Patient toolkit
Other resources
Tiglutik FAQs
No studies on riluzole in pregnant women are available. Case reports have been insufficient to determine the associated risk. The background risk for major birth defects and miscarriage in ALS patients and the general population is also unknown.
Oral administration of riluzole to pregnant animals resulted in decreased fetal growth, increased embryofetal mortality, and maternal toxicity at higher doses. These findings suggest potential developmental toxicity.
No data exists on riluzole presence in human milk or its effects on breastfed infants. However, riluzole or its metabolites have been detected in the milk of lactating rats. Consideration should be given to breastfeeding benefits and potential adverse effects on the infant.
In rats, oral administration of riluzole led to decreased fertility indices and increased embryolethality.
Safety and effectiveness for pediatric patients have not been established for riluzole.
In clinical studies, no significant differences in safety or effectiveness were observed between elderly and younger patients. However, some older individuals might exhibit increased sensitivity.
Patients with mild or moderate hepatic impairment might face increased risk of adverse reactions due to elevated riluzole exposure. TIGLUTIK is not recommended for certain patients with liver abnormalities.
Japanese patients might have higher riluzole concentrations, potentially leading to a greater risk of adverse reactions.
We receive information directly from the FDA and PrescriberPoint is updated as frequently as change are made available